Compare LIND & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | GHRS |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.2M | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | LIND | GHRS |
|---|---|---|
| Price | $20.07 | $15.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $19.00 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 866.0K | 286.8K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $736,447,000.00 | N/A |
| Revenue This Year | $19.55 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.50 | N/A |
| 52 Week Low | $7.45 | $7.98 |
| 52 Week High | $18.42 | $19.51 |
| Indicator | LIND | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 79.39 | 41.72 |
| Support Level | $16.30 | $13.60 |
| Resistance Level | $17.07 | $16.48 |
| Average True Range (ATR) | 0.66 | 0.92 |
| MACD | 0.17 | -0.35 |
| Stochastic Oscillator | 97.73 | 12.97 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.